AI Medical Service, one of the world's first real-time endoscopic artificial intelligence (AI) developers, has announced it has secured Breakthrough Device Designation by the FDA for its AI programs that analyse endoscopy images for potential diagnosis of gastric cancer. This designation will be critical as the company continues to accelerate clinical and regulatory programme especially in terms of prioritised review of the submission. At the same time as obtaining approval in its original country, Japan, the company will continue to work through the regulatory process in the US and other countries, and move on to global expansion.
Breakthrough Device Designation is granted to medical devices and device-led combination products that provide the potential for a more effective treatment option for life-threatening or irreversibly debilitating diseases. It expedites the traditional development, assessment and review process, and enables medical professionals to get access to new developments quickly.
AI Medical Service's system applies neural network algorithms which are trained with large real-world datasets of images of biopsy-proven cancer lesions, benign lesions, and normal tissue that were captured using standard endoscopes, thus aiding physicians performing endoscopies to detect lesions suspicious for cancer. AI Medical's technology is further differentiated as it is able to detect gastric, colorectal and oesophageal cancer, especially for concurrent usage whereas other entities' technology tends to focus only on colorectal cancer.
“We will launch this ground-breaking technology approved by the FDA as soon as possible in the US market,” said Dr Tomohiro Tada, CEO of AI Medical Services. “As our founding philosophy states, we plan to contribute to endoscopic medical treatment around the world.”